COMMUNIQUÉS West-GlobeNewswire

Quipt Home Medical Responds to Kanen Wealth Management

31/01/2025 - 13:30

Reaffirms commitment to enhancing shareholder value and strong corporate governance CINCINNATI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home [...]

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

31/01/2025 - 13:35

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

31/01/2025 - 14:00

— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch [...]

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

31/01/2025 - 14:00

DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered into a securities purchase agreement with a single institutional investor for [...]

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

31/01/2025 - 14:00

REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare [...]

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

31/01/2025 - 14:00

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]

Immutep Quarterly Activities Report Q2 FY25

31/01/2025 - 14:00

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT- [...]

Retrieve Medical Expands into Ambulatory Care with New Client Engagement

31/01/2025 - 14:00

BEDMINSTER, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Retrieve Medical, Inc. ( www.retrievemedical.com ) announces its expansion into the ambulatory care sector through a new client engagement with Saint Joseph’s Medical [...]

NewGen Announces Reverse Stock Split

31/01/2025 - 14:00

NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025 BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive [...]

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

31/01/2025 - 14:01

Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 [...]

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

31/01/2025 - 14:05

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the [...]

ARCPOINT ANNOUNCES C$800,000 NON-BROKERED PRIVATE PLACEMENT

31/01/2025 - 14:27

For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire Services Greenville, South Carolina, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint [...]

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

31/01/2025 - 14:30

● Q4 and FY Test volume increase 21% and 17% year-over-year ● Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“ [...]

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

31/01/2025 - 15:00

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025. Accordingly, any shares of the [...]

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

31/01/2025 - 15:00

CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, [...]

Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade

31/01/2025 - 15:00

Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion [...]

TerrAscend Announces Preliminary Fourth Quarter 2024 Financial Results and Schedules Earnings Conference Call

31/01/2025 - 15:15

Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Gross Profit Margin of 50.2%, an increase of 140 basis points quarter-over quarter Generated Positive Cashflow from Operations in the [...]

Heron’s Key Announces Exciting Expansion with Upcoming Pre-Sales

31/01/2025 - 17:00

GIG HARBOR, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Heron’s Key , a premier Life Plan Community member of Emerald Communities, is thrilled to announce the highly anticipated expansion of our community, with pre-sales [...]

Correction: GUERBET : Calendrier financier de l'exercice 2025

31/01/2025 - 17:45

RECTIFICATIF - Calendrier financier de l’exercice 2025 Villepinte, le 13 janvier 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son [...]